SEBI Reg. Investment Advisor

Download App
Help Center Subscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Influx Healthtech Ltd

BSE: 0 NSE: INFLUX ISIN: INE0MYZ01012
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Influx Healthtech Ltd belong to?
Influx Healthtech Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Influx Healthtech Ltd a good quality company?
Influx Healthtech Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Influx Healthtech Ltd undervalued or overvalued?
Influx Healthtech Ltd appears Fair, as its key valuation ratios are in line with their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios Current 3-year
Historic Median
Price to Earnings 26.29 36.75
Price to Book 13.13 11.99
Price to Sales 3.68 4.69
EV to EBITDA 17.26 23.65
Q.4 Is Influx Healthtech Ltd a good buy now?
Influx Healthtech Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Influx Healthtech Ltd?
Influx Healthtech Ltd revenue growth is 4.9% for FY-2025, which is below its 3-year CAGR of 20.99%, indicating slower growth.

Q.2 Gross Profit margin of Influx Healthtech Ltd?
Influx Healthtech Ltd Gross profit margin which is the profit after deduction of direct costs, is 19.8% for FY-2025, which is above its 3-year median of 16.8%, indicating increasing margins.

Q.3 Operating Profit Margin of Influx Healthtech Ltd?
Influx Healthtech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 19.64% for FY-2025, which is above its 3-year median of 16.97% indicating increasing margins.

Q.4 Net Profit Margin of Influx Healthtech Ltd?
Influx Healthtech Ltd Net Profit Margin is 12.75% for FY-2025, is above its 3-year median of 11.13%, indicating increasing margins.
Current Level 3-year
Historic Median
Gross Profit Margin (%) 19.8 16.8
Operating Profit Margin (%) 19.64 16.97
Net Profit Margin (%) 12.75 11.13

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Influx Healthtech Ltd?
Influx Healthtech Ltd Return on Asset is 24.1%, which is below its 3-year historical median of 31.35%, indicating deteriorated asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Influx Healthtech Ltd?
Influx Healthtech Ltd Return on capital employed is 60.15% for FY-2025, which is below its 3-year historical median of 85.26%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.

Q.7 Return on Equity (ROE) of Influx Healthtech Ltd?
Influx Healthtech Ltd Return on equity is 45.37% for FY-2025, which is below its 3-year historical median of 64.64%, indicating the business is making worse use of its shareholders capital.

Q.8 Cash conversion cycle of Influx Healthtech Ltd?
Influx Healthtech Ltd Cash conversion cycle is 22 days, above its 3-year historical median of 7 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level 3-year
Historic Median
Asset Turnover (x) 1.89 2.89
ROE (%) 45.37 64.64
ROCE (%) 60.15 85.26
Cash Conversion Cycle 22 days 7 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Influx Healthtech Ltd?
Influx Healthtech Ltd Debt-to-Equity ratio is 0.01, which is lower the industry average of 0.14, indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Influx Healthtech Ltd?
Influx Healthtech Ltd Debt to cash flow from operations is 0.03, which is at a healthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Influx Healthtech Ltd?

Q.1 Promoter shareholding and pledge status of Influx Healthtech Ltd?
Promoters hold 73.53% of the Influx Healthtech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Influx Healthtech Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Influx Healthtech Ltd vs industry peers?
Influx Healthtech Ltd revenue CAGR is 20.99%, compared to the industry median CAGR of 6.81%, indicating faster growth and gaining its market share.
Profit Metrics
Current Level 3-year
Industry Median
Revenue Growth (%) 4.9 6.8
Gross Profit Growth (%) 23.5 12.6
Operating Profit Growth (%) 23.5 9.5
Net Profit Growth (%) 18.2 8.6
Operating Efficiency
Current Level 3-year
Industry Median
Asset Turnover (x) 1.89 0.75
ROE (%) 45.37 9.05
ROCE (%) 60.15 11.33
Cash Conversion Cycle (days) 22.11 83

Valuation & price assessment

Q.1 Stock return of Influx Healthtech Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
9Y 5Y 3Y 1Y
Share Price
CAGR		 - - - -
Q.2 Valuation ratios of Influx Healthtech Ltd vs historical?
The current P/E ratio of 26.29 is lower than its historical median of 36.75, indicating that the stock is trading below its historical average valuation.
Q.3 How do the current valuation ratios compare with 3-year historical median and industry numbers?
Valuation Ratios Current 3-year
Historic Median		 3-year
Industry Median
Price to Earnings 26.29 36.75 33.73
Price to Book 13.13 11.99 3.09
Price to Sales 3.68 4.69 3.38
EV to EBITDA 17.26 23.65 16.04

Check more companies

1. Gland Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Wockhardt
5. Acutaas Chemicals
6. Sai Life Sciences
7. Neuland Laboratories
8. Piramal Pharma
9. Granules India
10. Pfizer

Check trending companies

1. KEC International Ltd.
2. ICICI Bank Ltd.
3. Godrej Agrovet Ltd.
4. Finolex Industries Ltd.
5. Emami Ltd.
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: